Table 1.
Clinical characterization of patients undergoing calcium acetate (CA) or sucroferric oxyhydroxide (SFO) as phosphate-binding agent
| Clinical parameter | CA | SFO |
|---|---|---|
| Age, years | 66.8 ± 13.9 | 61.1 ± 16.7 |
| Women, % | 40.0% | 42.9% |
| Arterial hypertension, % | 100.0% | 85.7% |
| Dyslipidaemia, % | 60.0% | 42.9% |
| Diabetes mellitus, % | 40.0% | 42.9% |
| Peripheral vascular disease, % | 40.0% | 14.3% |
| Stroke, % | 40.0% | 14.3% |
| Ischemic cardiomyopathy, % | 40.0% | 14.3% |
| Cancer, % | 20.0% | 28.6% |
| Catheter as a vascular access, % | 60.0% | 71.4% |
Values are means ± SD or relative frequencies (%). No statistically differences found between CA vs SFO